AVNS

Avanos Medical, Inc. Healthcare - Medical Devices Investor Relations →

NO
27.4% ABOVE
↓ Approaching Was 27.4% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $19.58
14-Week RSI 93
Rel. Volume (14w) This week's trading vs. the 14-week average 1.1x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.49

Avanos Medical, Inc. (AVNS) closed at $24.94 as of 2026-06-19, trading 27.4% above its 200-week moving average of $19.58. The stock is currently moving closer to the line, down from 27.4% last week. With a 14-week RSI of 93, AVNS is in overbought territory.

Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.49 ratio) is neutral — neither side is clearly dominating.

Over the past 560 weeks of data, AVNS has crossed below its 200-week moving average 9 times. On average, these episodes lasted 43 weeks. The average one-year return after crossing below was -3.7%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $1168 million, AVNS is a small-cap stock. The company generates a free cash flow yield of 1.5%. Return on equity stands at -9.2%. The stock trades at 1.5x book value.

Over the past 10.8 years, a hypothetical investment of $100 in AVNS would have grown to $87, compared to $467 for the S&P 500. AVNS has returned -1.3% annualized vs 15.3% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 1 open-market purchase totaling $659,300.

Free cash flow has been declining at a -15.6% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: AVNS vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After AVNS Crosses Below the Line?

Across 9 historical episodes, buying AVNS when it crossed below its 200-week moving average produced an average return of +0.4% after 12 months (median -15.0%), compared to +12.7% for the S&P 500 over the same periods. 44% of those episodes were profitable after one year. After 24 months, the average return was +14.1% vs +40.0% for the index.

Each line shows $100 invested at the moment AVNS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices AVNS would reach each dislocation threshold.

Current Bean Score +0.89σ
Current FCF Yield 0.64%
Baseline Yield 1.15%
Historical σ 0.61pp

Dislocation Price Levels

Prices where AVNS's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-03-31).

LevelσPriceSignal
Deep Value+2σ$12.14Unusually cheap — potential buy zone
Value+1σ$22.62Cheap vs. own history
Fair Value+0σ$165.13Historical mean behavior
Expensive-1σN/AExpensive vs. own history
Deep Expensive-2σN/AUnusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 22 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

11 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from AVNS's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation N/A Dividend yield vs own 10-yr norm
Drawdown Score -1.58σ Distance from line vs own history
Sector-Relative -0.84σ Vs sector median this week
Buyback Acceleration +1.2pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity 76th TTM buys / market cap, percentile of buyers
FCF Yield vs History -5.1pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+11.3pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Insider Buying Activity

1 conviction buy in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2025-08-13BLACKFORD GARY DDirector$659,30060,000N/A

Historical Touches

AVNS has crossed below its 200-week MA 9 times with an average 1-year return of +-3.7% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Sep 2015Aug 20164437.9%+20.3%-13.4%
Sep 2016Nov 20161010.9%+31.2%-28.6%
May 2017May 201720.6%+47.7%-31.1%
Dec 2018Jan 201914.1%-14.9%-37.4%
Mar 2019Mar 201911.3%-48.3%-39.0%
May 2019Jun 201939.3%-31.5%-39.3%
Jul 2019Oct 20191422.2%-17.1%-37.7%
Nov 2019Nov 20205450.6%+11.9%-29.8%
May 2021Apr 202625853.0%-32.6%-39.4%
Average43+-3.7%

Frequently Asked Questions

Is AVNS below its 200-week moving average?

No. Avanos Medical, Inc. (AVNS) is currently 27.4% above its 200-week moving average of $19.58. It would need to fall to $19.58 to cross below the line.

What is AVNS's 200-week moving average price?

Avanos Medical, Inc.'s 200-week moving average is $19.58 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when AVNS drops below its 200-week moving average?

AVNS has crossed below its 200-week moving average 9 times in our data. The average one-year return after these crossings was -3.7%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 43 weeks on average.

Is AVNS a good value right now?

Here's what our data says about AVNS as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 93 (overbought). Free cash flow yield is 1.5%. Return on equity is -9.2%. Price-to-book is 1.5x. This is not a buy or sell recommendation — always do your own research.

How does AVNS compare to the S&P 500?

Over the past 10.8 years, $100 invested in AVNS would have grown to $87, compared to $467 for the S&P 500. That's -1.3% annualized vs 15.3% for the index. AVNS has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-06-19